Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

January 01, 1996; Volume 24,Issue 1
  • You have access
    Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9.
    J P Jones, M He, W F Trager and A E Rettie
    Drug Metabolism and Disposition January 1996, 24 (1) 1-6;
  • You have access
    Trout liver slices for metabolism and toxicity studies.
    Y Singh, J B Cooke, D E Hinton and M G Miller
    Drug Metabolism and Disposition January 1996, 24 (1) 7-14;
  • You have access
    Cytochrome P4502E1- and cytochrome P4502B1/2B2-catalyzed carbon tetrachloride metabolism: effects on signal transduction as demonstrated by altered immediate-early (c-Fos and c-Jun) gene expression and nuclear AP-1 and NF-kappa B transcription factor levels.
    A Gruebele, K Zawaski, D Kaplan and R F Novak
    Drug Metabolism and Disposition January 1996, 24 (1) 15-22;
  • You have access
    Erythromycin as a specific substrate for cytochrome P4503A isozymes and identification of a high-affinity erythromycin N-demethylase in adult female rats.
    X J Zhang and P E Thomas
    Drug Metabolism and Disposition January 1996, 24 (1) 23-27;
  • You have access
    Gender differences in toxicokinetics, liver metabolism, and plasma esterase activity: observations from a chronic (27-week) toxicity study of enalapril/diltiazem combinations in rats.
    L E Los, D A Welsh, E G Herold, W J Bagdon and A G Zacchei
    Drug Metabolism and Disposition January 1996, 24 (1) 28-33;
  • You have access
    The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions.
    J P Chism and D E Rickert
    Drug Metabolism and Disposition January 1996, 24 (1) 34-40;
  • You have access
    N-acetyl-S-(1,2,2-trichlorovinyl)-L-cysteine and 2,2,2-trichloroethanol: two novel metabolites of tetrachloroethene in humans after occupational exposure.
    G Birner, A Rutkowska and W Dekant
    Drug Metabolism and Disposition January 1996, 24 (1) 41-48;
  • You have access
    Pharmacokinetics of stable isotopically labeled L-histidine in humans and the assessment of in vivo histidine ammonia lyase activities.
    T Furuta, K Okamiya, H Shibasaki and Y Kasuya
    Drug Metabolism and Disposition January 1996, 24 (1) 49-54;
  • You have access
    Synthesis of putative metabolites and investigation of the metabolic fate of gliclazide, [1-(3-azabicyclo(3,3,0)oct-3-yl)-3-(4-methylphenylsulfonyl) urea], in diabetic patients.
    A R Taylor, R D Brownsill, H Grandon, F Lefoulon, A Petit, W Luijten, P G Kopelman and B Walther
    Drug Metabolism and Disposition January 1996, 24 (1) 55-64;
  • You have access
    Metabolism of the bisphosphonate ester U-91502 in rats.
    J G Slatter, K L Feenstra, M J Hauer, D A Kloosterman, A H Parton, P E Sanders, G Scott and W Speed
    Drug Metabolism and Disposition January 1996, 24 (1) 65-73;
  • You have access
    Participation of cytochromes P4502B and P4503A in cocaine toxicity in rat hepatocytes.
    T S Poet, C A McQueen and J R Halpert
    Drug Metabolism and Disposition January 1996, 24 (1) 74-80;
  • You have access
    Mouse liver microsomal metabolism of chloral hydrate, trichloroacetic acid, and trichloroethanol leading to induction of lipid peroxidation via a free radical mechanism.
    Y C Ni, T Y Wong, R V Lloyd, T M Heinze, S Shelton, D Casciano, F F Kadlubar and P P Fu
    Drug Metabolism and Disposition January 1996, 24 (1) 81-90;
  • You have access
    Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.
    R H Barbhaiya, K A Dandekar and D S Greene
    Drug Metabolism and Disposition January 1996, 24 (1) 91-95;
  • You have access
    Disposition kinetics of human epidermal growth factor (hEGF1-53) and its truncated fragment (hEGF1-48) in rats.
    B S Kuo, G D Nordblom, R C Dudeck, L S Kirkish and D S Wright
    Drug Metabolism and Disposition January 1996, 24 (1) 96-104;
  • You have access
    The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine.
    R A Yokel, K A Meurer, T L Skinner and A M Fredenburg
    Drug Metabolism and Disposition January 1996, 24 (1) 105-111;
  • You have access
    Propranolol hydroxylation and N-desisopropylation by cytochrome P4502D6: studies using the yeast-expressed enzyme and NADPH/O2 and cumene hydroperoxide-supported reactions.
    N Bichara, M S Ching, C L Blake, H Ghabrial and R A Smallwood
    Drug Metabolism and Disposition January 1996, 24 (1) 112-118;
  • You have access
    Identification of beta-glucuronidase-resistant diastereomeric glucuronides of 3-hydroxy-3-methyloxindole formed during 3-methylindole metabolism in goats.
    D J Smith, M L Appleton, J R Carlson and G S Yost
    Drug Metabolism and Disposition January 1996, 24 (1) 119-125;
  • You have access
    [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10.
    A D Rodrigues, M J Kukulka, E M Roberts, D Ouellet and T R Rodgers
    Drug Metabolism and Disposition January 1996, 24 (1) 126-136;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 24, Issue 1
1 Jan 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Read
Loading
  • Cannabinoid Metabolites as CYP450 Inhibitors
  • Physiology of the Neonatal Gastrointestinal System
  • Pharmacokinetics and Disposition of Biologics
  • Alternative P450 Splicing Redirects Human Drug Metabolism
  • Switch from CAR to PXR in the Presence of EGF
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics